Palladium telluride quantum dots and cytochrome P450 biosensor for the detection of breast cancer drug – tamoxifen.
2015 (English)In: Sweden-Japan Seminar on Nanomaterials and Nanotechnology – SJS-Nano, Linköping, Sweden, 10-11 March 2015., Japan Society for the Promotion of Science (JSPS), Stockholm. , 2015Conference paper, Poster (Refereed)
Tamoxifen is an oral non-steroidal anti-estrogen drug used in the prevention and treatment of all stages of breast cancer. This drug acts by competing with estrogen for binding to the estrogen receptor (ER) and reduces the transcription of estrogen dependent genes. However, approximately 30-50% of ER-positive breast cancer patients either fail to respond or eventually become resistant to tamoxifen resulting in a serious clinical challenge in breast cancer management. This, therefore, calls for new selective and sensitive methods for evaluating individual’s metabolic activities of the drug ensuring in this way reliable dosing of the drug. This paper presents a biosensor system based on the combination of thioglycolic acid-capped palladium telluride (TGA-PdTe) quantum dots (QDs) and cytochrome P450-3A4 or 2D6 (CYP3A4 or CYP2D6) enzymes for the determination of tamoxifen. Preliminary FTIR and UVs studies of the QDs confirmed the presence of the capping agent via the specific COOH and CH2 signature bands; furthermore the adsorption band at ca. 330 nm and the corresponding band gap energy, Eg, value is 3.47 eV (within the Eg value for QDs particles) confirmed the successful synthesis of the TGA-PdTe QDs. Differential pulse voltammetric (DPV) electroanalysis using the Au|Cyst|TGA-PdTeQDs|CYP3A4 (or CYP2D6) biosensor systems indicated a clear catalytic cathodic peak at -0.35 V for the tamoxifen biotransformation reaction; this signal was used, in this work, as the biosensor analytical response. The developed biosensor presented a limit of detection (LOD) of 0.98 and 2.5 ng/mL, for CYP3A4 and CYP2D6 based biosensors, respectively. These are lower than tamoxifen’s maximum steady state plasma concentration (Cmax 40 ng/L) value; these performances make the proposed biosensor a promising platform for monitoring the drug in patients.
Place, publisher, year, edition, pages
Japan Society for the Promotion of Science (JSPS), Stockholm. , 2015.
IdentifiersURN: urn:nbn:se:liu:diva-118109OAI: oai:DiVA.org:liu-118109DiVA: diva2:813195
Sweden-Japan Seminar on Nanomaterials and Nanotechnology – SJS-Nano, Linköping, Sweden, 10-11 March 2015.
ProjectsIRSES - SAMERTCANCERSENS
FunderEU, FP7, Seventh Framework Programme, 318053